CompletedPhase 3ACTRN12607000041459

Efficacy study of adding chemotherapy to radiotherapy for treating bladder cancer

Trans Tasman Radiation Oncology Group (TROG) 02.03 - Multicentre Phase III study comparing Radical Synchronous Chemo-Radiation (cisplatin) vs Radical Radiation Alone in the Definitive Management of Muscle Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder Following Maximal Trans-Urethral Resection to reduce invasive local failure.

Sponsor

Kumar Gogna

Enrollment

150 participants

Start Date

Oct 11, 2002

Study Type

Interventional

Conditions

Transitional Cell Carcinoma of Urinary bladder

Summary

Radiation and chemotherapy both work in people with muscle-invasive bladder cancer. This study will determine if giving them together improves the results for people with this disease that seems to be confined to the bladder, but who are felt to be suitable candidates for bladder preserving treatment.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study is looking at: Efficacy study of adding chemotherapy to radiotherapy for treating bladder cancer. It is open to Both males and females, aged 18 and older. To take part, you generally need: Maximal Trans Urethral Resection (TUR). N.B. Previous: a) partial cystectomy. There are also some health conditions and factors that may prevent you from joining.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

ARM A: Synchronous chemo/radiation therapy. Weekly infusional cisplatin 35mg/m sqaured x 6 doses plus radiation 64Gy/32 fractions over 6 1/2 weeks.

Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000041459